1 citations,
August 2023 in “Acta dermato-venereologica” Corticosteroids are the most common treatment for alopecia areata, but many patients need better options.
7 citations,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
6 citations,
November 2022 in “Journal of autoimmunity” JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
40 citations,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
37 citations,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
8 citations,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
23 citations,
February 2021 in “Dermatologic therapy” Some treatments like pentoxifylline with topical corticosteroids might work for alopecia areata, but more research is needed to find the best one.
22 citations,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
54 citations,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
63 citations,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
130 citations,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
290 citations,
December 2017 in “Journal of The American Academy of Dermatology” Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.
27 citations,
September 2017 in “Archives of Dermatological Research” Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.
47 citations,
June 2017 in “Journal of dermatology” New treatments for alopecia areata show promise, but no cure exists and responses to treatments vary.
238 citations,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
222 citations,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
16 citations,
December 2015 in “Journal of Investigative Dermatology” Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.
